Skip to content

Study · Randomized controlled trial · n = 15 · 2013

4 results

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.

Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC and 6 more

Show all authors

Keefe RS, McEvoy JP, McMahon RP, Marder SR, Peterson BS, Lieberman JA

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology16 Jan 2013Cited by 54 (Europe PMC)

PMID23325325 (opens in a new tab)PMCIDPMC3656368 (opens in a new tab)DOI10.1038/npp.2013.23 (opens in a new tab)PepBankPUB-23325325
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In schizophrenia, high-dose davunetide showed a trend toward an 8.0% NAA/Cr increase over placebo (P=0.072).

    In plain wordsIn people with schizophrenia, high-dose davunetide showed a trend toward higher NAA/Cr than placebo.

    Peptide
    Davunetide
    Outcome
    IncreaseNAA/Cr, high dose
    Study

    n = 15

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 mg/day · 12 weeksAs given in this study (human).

    Measurements

    NAA/Cr increase
    8%
    high-dose versus placebo
    P value
    0.072 NA
    high-dose versus placebo

    Source sentences

    Summary
    NAA/Cr in the high-dose davunetide group (N=8) suggested a trend increase of 8.0% (P=0.072) over placebo (N=7).
    2 context sentences
    Summary · context
    In a subset of these subjects, proton magnetic resonance spectroscopy ((1)H-MRS) was conducted to explore the effects of davunetide on change in NAA/creatine (NAA/Cr) and choline/creatine (choline/Cr) over 12 weeks of treatment.
    Summary · context
    Of 63 outpatients with schizophrenia who received randomized davunetide (5 and 30 mg/day) or placebo in the parent clinical trial, 18 successfully completed (1)H-MRS in dorsolateral prefrontal cortex (DLPFC) at baseline and at 12 weeks.
  2. 02HumanRandomized controlled trialMechanism

    In schizophrenia, NAA/Cr was unchanged in the combined davunetide dose groups.

    In plain wordsIn people with schizophrenia, the combined davunetide groups showed unchanged NAA/Cr.

    Peptide
    Davunetide
    Outcome
    No significant changeNAA/Cr, combined doses
    Study

    n = 11

    Analysis
    Exploratory
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 and 30 mg/day · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    NAA/Cr was unchanged for combined high- and low-dose davunetide groups (N=11).
    2 context sentences
    Summary · context
    In a subset of these subjects, proton magnetic resonance spectroscopy ((1)H-MRS) was conducted to explore the effects of davunetide on change in NAA/creatine (NAA/Cr) and choline/creatine (choline/Cr) over 12 weeks of treatment.
    Summary · context
    Of 63 outpatients with schizophrenia who received randomized davunetide (5 and 30 mg/day) or placebo in the parent clinical trial, 18 successfully completed (1)H-MRS in dorsolateral prefrontal cortex (DLPFC) at baseline and at 12 weeks.
  3. 03HumanRandomized controlled trialMechanism

    In schizophrenia, combined davunetide doses suggested a 6.4% choline/Cr increase over placebo (P=0.069).

    In plain wordsIn people with schizophrenia, combined davunetide doses suggested higher choline/Cr than placebo.

    Peptide
    Davunetide
    Outcome
    IncreaseCholine/Cr, combined doses
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 and 30 mg/day · 12 weeksAs given in this study (human).

    Measurements

    Choline/Cr increase
    6.4%
    combined doses versus placebo
    P value
    0.069 NA
    combined doses versus placebo

    Source sentences

    Summary
    Choline/Cr for combined high- and low-dose davunetide groups suggested a 6.4% increase (P=0.069), while the high-dose group showed a 7.9% increase (P=0.040) over placebo.
    2 context sentences
    Summary · context
    In a subset of these subjects, proton magnetic resonance spectroscopy ((1)H-MRS) was conducted to explore the effects of davunetide on change in NAA/creatine (NAA/Cr) and choline/creatine (choline/Cr) over 12 weeks of treatment.
    Summary · context
    Of 63 outpatients with schizophrenia who received randomized davunetide (5 and 30 mg/day) or placebo in the parent clinical trial, 18 successfully completed (1)H-MRS in dorsolateral prefrontal cortex (DLPFC) at baseline and at 12 weeks.
  4. 04HumanRandomized controlled trialMechanism

    In schizophrenia, high-dose davunetide increased choline/Cr by 7.9% over placebo (P=0.040).

    In plain wordsIn people with schizophrenia, high-dose davunetide increased choline/Cr compared with placebo.

    Peptide
    Davunetide
    Outcome
    IncreaseCholine/Cr, high dose
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 mg/day · 12 weeksAs given in this study (human).

    Measurements

    Choline/Cr increase
    7.9%
    high-dose versus placebo
    P value
    0.04 NA
    high-dose versus placebo

    Source sentences

    Summary
    Choline/Cr for combined high- and low-dose davunetide groups suggested a 6.4% increase (P=0.069), while the high-dose group showed a 7.9% increase (P=0.040) over placebo.
    2 context sentences
    Summary · context
    In a subset of these subjects, proton magnetic resonance spectroscopy ((1)H-MRS) was conducted to explore the effects of davunetide on change in NAA/creatine (NAA/Cr) and choline/creatine (choline/Cr) over 12 weeks of treatment.
    Summary · context
    Of 63 outpatients with schizophrenia who received randomized davunetide (5 and 30 mg/day) or placebo in the parent clinical trial, 18 successfully completed (1)H-MRS in dorsolateral prefrontal cortex (DLPFC) at baseline and at 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.